Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

3.46
+0.14004.22%
Post-market: 3.43-0.0300-0.87%16:15 EDT
Volume:3.25M
Turnover:11.13M
Market Cap:298.29M
PE:-0.92
High:3.52
Open:3.30
Low:3.27
Close:3.32
52wk High:19.11
52wk Low:3.05
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.18
T/O Rate:5.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:1.79
PE(LYR):-1.09

Loading ...

EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing?

Simply Wall St.
·
Jul 14

Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jul 13

Eyepoint Appoints Tarek S. Hassan, M.d., as Chief Strategic Science Officer

THOMSON REUTERS
·
Jul 13

Press Release: Eyepoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Dow Jones
·
Jul 13

Eyepoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
Jul 08

Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated

TIPRANKS
·
Jul 06

Eyepoint Chief Medical Officer Ramiro Ribeiro Disposes of 4,875 Common Shares Worth $73,167.95

Reuters
·
Jul 03

Eyepoint Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 01

Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating

MT Newswires Live
·
Jul 01

EyePoint price target raised to $65 from $29 at Chardan

TIPRANKS
·
Jul 01

Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 25

Eyepoint Pharmaceuticals Price Target Maintained with a $68.00/share by Guggenheim

Dow Jones
·
Jun 24

Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 24

EyePoint shareholders approve 4.9 million-share increase to 2023 incentive plan

Reuters
·
Jun 22

EyePoint grants inducement stock options for 39,700 shares at $12.08 each

Reuters
·
Jun 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 16

Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43

TIPRANKS
·
Jun 12

EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease

TIPRANKS
·
Jun 04

Phase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)

Simply Wall St.
·
May 22